Israel Barken1, Jack Geller, Moshe Rogosnitzky. 1. Prostate Cancer Research and Education Foundation, 5520 Wellesley St., Suite 103 B, La Mesa, CA 91942-2015, USA. drbarken@pcref.org
Abstract
BACKGROUND: Noscapine, a non-toxic alkaloid and common constituent of cough medicine, stabilises tubulin. It inhibits the growth of several human and murine neoplasms, with no significant toxicity. Its effect on prostate cancer has not been evaluated. MATERIALS AND METHODS: Noscapine was administered orally (300 mg/kg per day) for 56 days to PC3 human prostate cancer-bearing immunodeficient mice (n=10). Immunodeficient control mice (n=10) received only diluent in an identical regimen. RESULTS: Mean total tumour weight was 0.42 +/- 0.23 g and 0.97 +/- 0.31 g (p<0.001) in the noscapine-treated group and the control group, respectively, without evidence of toxicity. Metastases occurred less frequently in the treatment than the control group (30% vs. 90%; p<0.05). CONCLUSION: Oral administration of noscapine limited tumour growth and lymphatic metastasis of PC3 human prostate cancer in this mouse model, supporting its therapeutic potential as a nontoxic and easily administered treatment for metastatic cancer.
BACKGROUND:Noscapine, a non-toxic alkaloid and common constituent of cough medicine, stabilises tubulin. It inhibits the growth of several human and murineneoplasms, with no significant toxicity. Its effect on prostate cancer has not been evaluated. MATERIALS AND METHODS:Noscapine was administered orally (300 mg/kg per day) for 56 days to PC3humanprostate cancer-bearing immunodeficientmice (n=10). Immunodeficient control mice (n=10) received only diluent in an identical regimen. RESULTS: Mean total tumour weight was 0.42 +/- 0.23 g and 0.97 +/- 0.31 g (p<0.001) in the noscapine-treated group and the control group, respectively, without evidence of toxicity. Metastases occurred less frequently in the treatment than the control group (30% vs. 90%; p<0.05). CONCLUSION: Oral administration of noscapine limited tumour growth and lymphatic metastasis of PC3humanprostate cancer in this mouse model, supporting its therapeutic potential as a nontoxic and easily administered treatment for metastatic cancer.
Authors: David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn Journal: Curr Drug Targets Date: 2010-07 Impact factor: 3.465
Authors: Louis T P Martin; Mark W Nachtigal; Tamara Selman; Elaine Nguyen; Jayme Salsman; Graham Dellaire; Denis J Dupré Journal: Mol Cell Biochem Date: 2018-10-22 Impact factor: 3.396
Authors: Jacob Kach; Nathan Sandbo; Jennifer La; Darcy Denner; Eleanor B Reed; Olga Akimova; Svetlana Koltsova; Sergei N Orlov; Nickolai O Dulin Journal: J Biol Chem Date: 2014-02-03 Impact factor: 5.157
Authors: Yanran Li; Sijin Li; Kate Thodey; Isis Trenchard; Aaron Cravens; Christina D Smolke Journal: Proc Natl Acad Sci U S A Date: 2018-04-02 Impact factor: 11.205